{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:59:59Z","timestamp":1790949599792,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372061"],"award-info":[{"award-number":["82372061"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472081"],"award-info":[{"award-number":["82472081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402403"],"award-info":[{"award-number":["82402403"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong","doi-asserted-by":"crossref","award":["2024A1515010608"],"award-info":[{"award-number":["2024A1515010608"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12072-025-10777-8","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T16:44:44Z","timestamp":1739292284000},"page":"560-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and\/or right atrium tumor thrombus"],"prefix":"10.1007","volume":"19","author":[{"given":"Suixing","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhe","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwen","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genjun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-8895","authenticated-orcid":false,"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"3","key":"10777_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10777_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.510290145","volume":"29","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62\u201367","journal-title":"Hepatology"},{"issue":"11","key":"10777_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/j.1872-034X.2010.00731.x","volume":"40","author":"I Ikai","year":"2010","unstructured":"Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010;40(11):1043\u20131059","journal-title":"Hepatol Res"},{"issue":"1","key":"10777_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jvir.2008.09.030","volume":"20","author":"IJ Lee","year":"2009","unstructured":"Lee IJ, Chung JW, Kim HC, Yin YH, So YH, Jeon UB, et al. Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors. J vasc Interv Radiol. 2009;20(1):22\u201329","journal-title":"J vasc Interv Radiol"},{"issue":"5","key":"10777_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.amjcard.2008.04.042","volume":"102","author":"AD Sung","year":"2008","unstructured":"Sung AD, Cheng S, Moslehi J, Scully EP, Prior JM, Loscalzo J. Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature. Am J Cardiol. 2008;102(5):643\u2013645","journal-title":"Am J Cardiol"},{"issue":"12","key":"10777_CR6","first-page":"4641","volume":"31","author":"YH Chun","year":"2011","unstructured":"Chun YH, Ahn SH, Park JY, Kim DY, Han KH, Chon CY, et al. Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava\/heart invasion. Anticancer Res. 2011;31(12):4641\u20134646","journal-title":"Anticancer Res"},{"issue":"3","key":"10777_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1245\/s10434-012-2646-2","volume":"20","author":"Y Wang","year":"2013","unstructured":"Wang Y, Yuan L, Ge RL, Sun Y, Wei G. Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava\/right atrium tumor thrombus: results of a retrospective cohort study. Ann Surg Oncol. 2013;20(3):914\u2013922","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10777_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u2013693","journal-title":"J Hepatol"},{"issue":"3","key":"10777_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns S, Corbett V, Yarchoan M, Finn RS, Llovet JM. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. Jama Oncol. 2024;10(3):395\u2013404","journal-title":"Jama Oncol"},{"issue":"13","key":"10777_CR10","first-page":"9","volume":"81","author":"R Finn","year":"2021","unstructured":"Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T, et al. Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). Cancer Res. 2021;81(13):9","journal-title":"Cancer Res"},{"issue":"4","key":"10777_CR11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u2013873","journal-title":"J Hepatol"},{"issue":"1","key":"10777_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1055-3207(02)00082-0","volume":"12","author":"I Ikai","year":"2003","unstructured":"Ikai I, Yamamoto Y, Yamamoto N, Terajima H, Hatano E, Shimahara Y, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and\/or hepatic veins. Surg Oncol Clin N Am. 2003;12(1):65\u201375","journal-title":"Surg Oncol Clin N Am"},{"issue":"3","key":"10777_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","volume":"31","author":"LT Chen","year":"2020","unstructured":"Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO. MOS and SSO Ann Oncol. 2020;31(3):334\u2013351","journal-title":"MOS and SSO Ann Oncol"},{"issue":"5","key":"10777_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.21.01963","volume":"40","author":"N Lyu","year":"2022","unstructured":"Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468\u2013480","journal-title":"J Clin Oncol"},{"issue":"2","key":"10777_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1148\/117.2.303","volume":"117","author":"K Okuda","year":"1975","unstructured":"Okuda K, Musha H, Yoshida T, Kanda Y, Yamazaki T. Demonstration of growing casts of hepatocellular carcinoma in the portal vein by celiac angiography: the thread and streaks sign. Radiology. 1975;117(2):303\u2013309","journal-title":"Radiology"},{"issue":"16","key":"10777_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16177","volume":"42","author":"S Zhong","year":"2024","unstructured":"Zhong S, Lyu N, Zhao M. Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and\/or right atrium tumor thrombus. J Clin Oncol. 2024;42(16): e16177","journal-title":"J Clin Oncol"},{"issue":"3","key":"10777_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816\u2013830","journal-title":"Radiology"},{"issue":"3","key":"10777_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1499-3872(13)60043-0","volume":"12","author":"AJ Li","year":"2013","unstructured":"Li AJ, Zhou WP, Lin C, Lang XL, Wang ZG, Yang XY, et al. Surgical treatment of hepatocellular carcinoma with inferior vena cava tumor thrombus: a new classification for surgical guidance. Hepatob Pancreat Dis. 2013;12(3):263\u2013269","journal-title":"Hepatob Pancreat Dis"},{"issue":"9","key":"10777_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00595-017-1619-2","volume":"48","author":"K Sakamoto","year":"2018","unstructured":"Sakamoto K, Nagano H. Outcomes of surgery for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium. Surg Today. 2018;48(9):819\u2013824","journal-title":"Surg Today"},{"key":"10777_CR20","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice Guilelines in oncology: Hepatocellular Carcinoma. Version 2. 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1514. Accessed August 30, 2024."},{"issue":"5","key":"10777_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver cancer. 2023;12(5):405\u2013444","journal-title":"Liver cancer."},{"issue":"1","key":"10777_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","volume":"18","author":"M Zhao","year":"2024","unstructured":"Zhao M, Guo Z, Zou YH, Li X, Yan ZP, Chen MS, et al. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatol Int. 2024;18(1):4\u201331","journal-title":"Hepatol Int"},{"issue":"2","key":"10777_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"1","key":"10777_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360","journal-title":"Semin Liver Dis"},{"key":"10777_CR25","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2147\/JHC.S410967","volume":"10","author":"S Ning","year":"2023","unstructured":"Ning S, Li X, Ma X, Liu J, Chang X. Efficacy of TACE combined with lenvatinib plus sintilimab for hepatocellular carcinoma with tumor thrombus in the inferior vena cava and\/or right atrium. J Hepatocell Carcinoma. 2023;10:1511\u20131525","journal-title":"J Hepatocell Carcinoma"},{"issue":"6","key":"10777_CR26","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/hep.26586","volume":"58","author":"M Reig","year":"2013","unstructured":"Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 2013;58(6):2023\u20132031","journal-title":"Hepatology"},{"issue":"10","key":"10777_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","volume":"16","author":"J Bruix","year":"2019","unstructured":"Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16(10):617\u2013630","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10777_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","volume":"174","author":"Z Lai","year":"2022","unstructured":"Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68\u201377","journal-title":"Eur J Cancer"},{"issue":"1","key":"10777_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"TQ Zhang","year":"2023","unstructured":"Zhang TQ, Geng ZJ, Zuo MX, Li JB, Huang JH, Huang ZL, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023;8(1):413","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10777_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1008866","volume":"4","author":"J Pol","year":"2015","unstructured":"Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. Trial watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015;4(4): e1008866","journal-title":"Oncoimmunology"},{"issue":"6","key":"10777_CR31","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","volume":"43","author":"H Zhu","year":"2020","unstructured":"Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol. 2020;43(6):1203\u20131214","journal-title":"Cell Oncol"},{"issue":"5","key":"10777_CR32","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/SLA.0000000000002135","volume":"267","author":"DD Aufhauser Jr","year":"2018","unstructured":"Aufhauser DD Jr, Sadot E, Murken DR, Eddinger K, Hoteit M, Abt PL, et al. Incidence of occult intrahepatic metastasis in hepatocellular carcinoma treated with transplantation corresponds to early recurrence rates after partial hepatectomy. Ann Surg. 2018;267(5):922\u2013928","journal-title":"Ann Surg"},{"key":"10777_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/JHC.S285357","volume":"7","author":"HA Lee","year":"2020","unstructured":"Lee HA, Rim CH. Efficacy of local treatments for hepatocellular carcinoma involving the inferior vena cava and\/or right atrium. J Hepatocell Carcinoma. 2020;7:435\u2013446","journal-title":"J Hepatocell Carcinoma"},{"key":"10777_CR34","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice Guilelines in oncology: Hepatocellular Carcinoma. Version 2. 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatocellular.pdf. Accessed April 30, 2024."},{"issue":"6","key":"10777_CR35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.21037\/hbsn.2019.10.07","volume":"9","author":"ZH Chen","year":"2020","unstructured":"Chen ZH, Wang K, Zhang XP, Feng JK, Chai ZT, Guo WX, et al. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobil Surg Nutr. 2020;9(6):717\u2013728","journal-title":"Hepatobil Surg Nutr"},{"issue":"3","key":"10777_CR36","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1097\/SLA.0000000000005789","volume":"278","author":"A Ichida","year":"2023","unstructured":"Ichida A, Kokudo T, Shimada S, Hatano E, Kubo S, Kato Y, et al. Liver resection for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium: a large-scale multicenter survey conducted in Japan. Ann Surg. 2023;278(3):e549\u2013e555","journal-title":"Ann Surg"},{"issue":"1","key":"10777_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijrobp.2009.07.1730","volume":"78","author":"JE Koo","year":"2010","unstructured":"Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol. 2010;78(1):180\u2013187","journal-title":"Int J Radiat Oncol"},{"issue":"12","key":"10777_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/jhbp.865","volume":"28","author":"HA Lee","year":"2021","unstructured":"Lee HA, Park S, Seo YS, Yoon WS, Shin IS, Rim CH. Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: a systematic review and meta-analysis. J Hepatobiliary Pancreat Sci. 2021;28(12):1031\u20131046","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"4","key":"10777_CR39","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00270-008-9342-4","volume":"31","author":"MC Chern","year":"2008","unstructured":"Chern MC, Chuang VP, Cheng T, Lin ZH, Lin YM. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. Cardiovasc Inter Rad. 2008;31(4):735\u2013744","journal-title":"Cardiovasc Inter Rad"},{"key":"10777_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.879454","volume":"12","author":"Y Qian","year":"2022","unstructured":"Qian Y, Gong L, Li S, Mao K, Li X, Liao G. Case report: radiotherapy plus immunotherapy and lenvatinib for the treatment of recurrent hepatocellular carcinoma with a right atrium and inferior vena cava tumor thrombus. Front Oncol. 2022;12: 879454","journal-title":"Front Oncol"},{"issue":"1","key":"10777_CR41","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236","journal-title":"J Hepatol"},{"issue":"3","key":"10777_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5320\/wjr.v6.i3.69","volume":"6","author":"QM Nhu","year":"2016","unstructured":"Nhu QM, Knowles H, Pockros PJ, Frenette CT. Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Respirol. 2016;6(3):69\u201375","journal-title":"World J Respirol"},{"issue":"12","key":"10777_CR43","first-page":"3929","volume":"109","author":"QF Chen","year":"2023","unstructured":"Chen QF, Lyu N, Wang X, Jiang XY, Hu Y, Chen S, et al. Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and\/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial. Int J Surg. 2023;109(12):3929\u20133939","journal-title":"Int J Surg"},{"issue":"7","key":"10777_CR44","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet oncol. 2021;22(7):977\u2013990","journal-title":"Lancet oncol"},{"issue":"12","key":"10777_CR45","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u20131410","journal-title":"Lancet Oncol"},{"issue":"10408","key":"10777_CR46","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u20131146","journal-title":"Lancet"},{"issue":"3","key":"10777_CR47","first-page":"141","volume":"86","author":"K Shirabe","year":"2001","unstructured":"Shirabe K, Shimada M, Tsujita E, Maehara S, Yamashita Y, Rikimaru T, et al. Thrombectomy before hepatic resection for hepatocellular carcinoma with a tumor thrombus extending to the inferior vena cava. Int Surg. 2001;86(3):141\u2013143","journal-title":"Int Surg"},{"issue":"6","key":"10777_CR48","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/jjco\/hym038","volume":"37","author":"M Mizumoto","year":"2007","unstructured":"Mizumoto M, Tokuuye K, Sugahara S, Hata M, Fukumitsu N, Hashimoto T, et al. Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus: report of three cases. Jpn J Clin Oncol. 2007;37(6):459\u2013462","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10777_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","volume":"8","author":"HD Zhu","year":"2023","unstructured":"Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8(1):58","journal-title":"Signal Transduct Target Ther"},{"key":"10777_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"ZC Jin","year":"2024","unstructured":"Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, et al. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study. EClinicalMedicine. 2024;72: 102622","journal-title":"EClinicalMedicine"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10777-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10777-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10777-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:03:06Z","timestamp":1749060186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10777-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10777"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10777-8","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethical Review Committees of all participating institutions, and all patients provided written informed consent. The procedures followed the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}